Publications and communications of Anna Lechanteur

Bya, L.-A., Coeurderoi, A., Dinh, T. N., Piel, G., Lechanteur, A., & Evrard, B. (31 January 2024). STUDY OF THE IMPACT OF DRYING PROCESSES ON POWDER PROPERTIES: A COMPARATIVE ANALYSIS OF SPRAY-DRYING TECHNOLOGY FROM SOLUTION AND SUSPENSION [Paper presentation]. CIRM day 2024 - Scientific Day, Liège, Belgium.

Koch, N., Jennotte, O., Lechanteur, A., Grignard, B., & Evrard, B. (17 January 2024). Improvement of aqueous solubility of active pharmaceutical ingredients by using mesoporous silica impregnation under pressurized carbon dioxide [Paper presentation]. 1st FRITCO2T Day.

Koch, N., Jennotte, O., Lechanteur, A., DEVILLE, M., Charlier, C., Cardot Jean-Michel, CHIAP, P., & Evrard, B. (2024). An Intravenous Pharmacokinetic Study of Cannabidiol Solutions in Piglets through the Application of a Validated Ultra-High-Pressure Liquid Chromatography Coupled to Tandem Mass Spectrometry Method for the Simultaneous Quantification of CBD and Its Carboxylated Metabolite in Plasma. Pharmaceutics. doi:10.3390/pharmaceutics16010140

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Maquoi, E., Pendeville-Samain, H., Evrard, B., Jérôme, C., Chain, J. L., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (2023). Poly(N-methyl‐N‐vinylacetamide): a strong alternative to PEG for lipid‐based nanocarriers delivering siRNA. Advanced Healthcare Materials, 2302712. doi:10.1002/adhm.202302712
* These authors have contributed equally to this work.

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (September 2023). Formulation and quality consideration of cannabidiol printed forms produced by fused-deposition modeling. Journal of Drug Delivery Science and Technology, 87, 104837. doi:10.1016/j.jddst.2023.104837

Lechanteur, A., Gresse, E., Orozco, L., Plougonven, E., Léonard, A., Vandewalle, N., Lumay, G., & Evrard, B. (16 August 2023). Inhalation powder development without carrier: how to engineer ultra-flying microparticles? European Journal of Pharmaceutics and Biopharmaceutics, 191, 26 - 35. doi:10.1016/j.ejpb.2023.08.010

Berger, M.* , Toussaint, F.* , Djemaa, S. B.* , Laloy, J., Pendeville-Samain, H., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D.* , Debuigne, A.* , & Piel, G.*. (02 August 2023). Poly(vinyl pyrrolidone) derivatives as PEG alternatives for stealth, non-toxic and less immunogenic siRNA-containing lipoplex delivery. Journal of Controlled Release, 361, 87 - 101. doi:10.1016/j.jconrel.2023.07.031
* These authors have contributed equally to this work.

Parulski, C., Bya, L.-A., Goebel, J., Servais, A.-C., Lechanteur, A., & Evrard, B. (13 June 2023). Development of 3D printed mini-waffle shapes containing hydrocortisone for children's personalized medicine. International Journal of Pharmaceutics, 642 (123131). doi:10.1016/j.ijpharm.2023.123131

Dinh, T. N., Bya, L.-A., Lechanteur, A., Penoy, N., Evrard, B., & Piel, G. (28 April 2023). LIPOSOME FOR THE TREATMENT OF COPD PRODUCED BY SUPERCRITICAL CARBON DIOXIDE-BASED TECHNOLOGIES [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (27 April 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticle tracking method [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Gresse, E., Rousseau, J., du Bois, A., Lechanteur, A., & Evrard, B. (27 April 2023). HOW TO IMPROVE ENGINEERED MICRONIZED POWDER FLOWABILITY? [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Parulski, C., Bya, L.-A., Goebel, J., Servais, A.-C., Lechanteur, A., & Evrard, B. (27 April 2023). The future of 3D printing for personalized medicine: Could 3D printed waffle shapes replace the magistral preparation of hydrocortisone capsules? [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (21 March 2023). Impact of the hydrophobic chain length of PEG derivatives on the behavior of LNPs in serum: Development of a Nanoparticle Tracking Analysis (NTA) Method [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.

Gresse, E., du Bois, A., Rousseau, J., Lechanteur, A., & Evrard, B. (20 March 2023). How to improve engineered micronized powder flowability? [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.

Jennotte, O., Lechanteur, A., Koch, N., Evrard, B., Rosoux François, Emmerechts Carl, & Beeckman Eric. (20 March 2023). Formulation and Quality Consideration of Printed Tablets of Cannabidiol Produced by Direct Powder Extrusion [Poster presentation]. 4th European Conference on Pharmaceutics.

Parulski, C., Goebel, J., Bya, L.-A., Lechanteur, A., & Evrard, B. (20 March 2023). Could 3D printed waffle shapes replace the magistral preparation of hydrocortisone capsules for children’s personalized medicine? [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (10 February 2023). Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method. Pharmaceutics, 15 (2). doi:10.3390/pharmaceutics15020597

Berger, M., Degey, M., Leblond Chain, J., Maquoi, E., Evrard, B., Lechanteur, A., & Piel, G. (01 February 2023). Effect of PEG anchor and serum on Lipid Nanoparticles: development of a nanoparticles tracking method [Paper presentation]. CIRM Day, Liege, Belgium.

Dinh, T. N., Bya, L.-A., Lechanteur, A., Penoy, N., Evrard, B., & Piel, G. (01 February 2023). Liposome containing ciclesonide with/without indacaterol produced by supercritical carbon dioxide-based technologies [Poster presentation]. CIRM Day, Liège, Belgium.

Dinh, T. N., Bya, L.-A., Lechanteur, A., Penoy, N., Evrard, B., & Piel, G. (01 February 2023). Liposome containing ciclesonide with/without indacaterol produced by supercritical carbon dioxide-based technologies [Poster presentation]. CIRM Day, Liège, Belgium.

Bya, L.-A., Dinh, T. N., Piel, G., Lechanteur, A., & Evrard, B. (2023). Inhaled dry powder containing lipid-nanoparticles: particle engineering by spray-drying technology [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Dinh, T. N., Bya, L.-A., Lechanteur, A., Penoy, N., Evrard, B., & Piel, G. (2023). LIPOSOME FOR THE TREATMENT OF COPD PRODUCED BY SUPERCRITICAL CARBON DIOXIDE-BASED TECHNOLOGIES [Paper presentation]. 21st Forum of Pharmaceutical Sciences, Blankenberge, Belgium.

Koch, N., Jennotte, O., Bourcy, Q., Lechanteur, A., Chiap, P., & Evrard, B. (2023). How the choice of dissolution parameters influences the interpretation of dissolution efficiency from two different cannabidiol formulations? [Poster presentation]. 4th European Conference on Pharmaceutics, Marseille, France.

Koch, N., Jennotte, O., Bourcy, Q., Lechanteur, A., & Evrard, B. (2023). How the choice of dissolution parameters influences the interpretation of dissolution efficiency from two different cannabidiol formulations? [Paper presentation]. CIRM day 2023.

Koch, N., Jennotte, O., Toussaint, C., Lechanteur, A., & Evrard, B. (2023). Production challenges of tablets containing lipid excipients: case study using cannabidiol as drug model. International Journal of Pharmaceutics, 122639. doi:10.1016/j.ijpharm.2023.122639

Nyamba, I., Jennotte, O., Charles B Sombié, Lechanteur, A., Sacre, P.-Y., Abdoulaye Djandé, Rasmane Semde, & Evrard, B. (2023). Preformulation study for the selection of a suitable polymer for the development of ellagic acid-based solid dispersion using hot-melt extrusion. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2023.123088

Parulski, C., Goebel, J., Bya, L.-A., Servais, A.-C., Lechanteur, A., & Evrard, B. (2023). Could 3D printed waffle shapes replace hydrocortisone capsules prepared in community pharmacies for children’s personalized medicine? [Paper presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Ayyoubi, S., Van Kampen, E., Kocabas, L. I., Parulski, C., Lechanteur, A., Evrard, B., De Jager, K., Muller, E., Wilms, E. W., Meulenhoff, P. W. C., & Ruijgrok, E. J. (December 2022). 3D printed, personalized sustained release cortisol for patients with adrenal insufficiency. International Journal of Pharmaceutics, 630, 122466. doi:10.1016/j.ijpharm.2022.122466

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (15 November 2022). Amphiphilic poly(N-vinylpyrrolidone)-based lipoplex modifiers for drug delivery applications [Paper presentation]. Belgian Polymer Group (BPG) Annual Meeting, Blankenberge, Belgium.

Gresse, E., du Bois, A., Lechanteur, A., & Evrard, B. (30 September 2022). How to improve engineered micronized powder flowability? [Paper presentation]. GALENUS WORKSHOP ON RECENT DEVELOPMENTS IN PARTICLE ENGINEERING, Graz, Austria.

Parulski, C., Gresse, E., Jennotte, O., Felten, A., Ziemons, E., Lechanteur, A., & Evrard, B. (31 August 2022). Fused deposition modeling 3D printing of solid oral dosage forms containing amorphous solid dispersions: How to elucidate drug dissolution mechanisms through surface spectral analysis techniques? International Journal of Pharmaceutics, 626, 122157. doi:10.1016/j.ijpharm.2022.122157

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (14 June 2022). Novel polyvinylpyrrolidone-based lipoplex modifiers for siRNA delivery [Poster presentation]. Bordeaux Polymer Conference, Bordeaux, France.

Toussaint, F., Berger, M., Lechanteur, A., Jérôme, C., Piel, G., & Debuigne, A. (01 June 2022). PNVP as PEG alternative for lipoplex modification in siRNA delivery application [Poster presentation]. Advanced Functional Polymers for Medecine (AFPM), Nice, France.

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (2022). Development of amorphous solid dispersions of cannabidiol: Influence of the carrier, the hot-melt extrusion parameters and the use of a crystallization inhibitor. Journal of Drug Delivery Science and Technology, 103372. doi:10.1016/j.jddst.2022.103372

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (30 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP World Meeting), Rotterdam, Netherlands.

Jennotte, O., Koch, N., Rosoux, F., Emmerechts Carl, Beeckman Eric, Lechanteur, A., & Evrard, B. (30 March 2022). Formulation and Quality Consideration of Cannabidiol Printlets Produced by Fused-Deposition Modeling [Poster presentation]. 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (30 March 2022). How do polymer composition and infill density of 3D printed oral forms influence the dissolution rate of a BCSII molecule ? [Poster presentation]. 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology (PBP), Rotterdam, Netherlands.

Nyamba, I., Jennotte, O., Charles B Sombié, Lechanteur, A., Rasmané Semdé, & Evrard, B. (27 March 2022). Polymer screening for the development of solid dispersion formulations based on ellagic acid by Hot melt extrusion [Poster presentation]. world meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, Rotterdam, Netherlands.

Lechanteur, A., Plougonven, E., Orozco Ardila, L., Gresse, E., Lumay, G., Vandewalle, N., Léonard, A., & Evrard, B. (25 March 2022). Engineered-inhaled particles: influence of carbohydrates excipients nature on powder properties and behavior [Poster presentation]. PBP world meeting 2022.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (10 March 2022). How do infill density and polymer composition of 3D printed solid oral forms impact the dissolution profile of a BSCII drug ? [Paper presentation]. CRS Local Chapters meeting Aachen, Aachen, Germany.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., & Piel, G. (09 March 2022). Development of innovative grafted lipoplexes using PNVP-derivatives polymers as a PEG alternative to treat cancer [Paper presentation]. 2022 Meeting of the Germany and BeNeLux & France Local Chapters of the Controlled Release Society in Aachen, Aachen, Germany.

Koch, N., Jennotte, O., Lechanteur, A., & Evrard, B. (March 2022). Cannabidiol tablets with an enhanced bioavailability: Optimal selection of excipients and tableting through Design of Experiments [Poster presentation]. PBP 13th World Meeting, Rotterdam, Netherlands.

Berger, M., Toussaint, F., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (02 February 2022). PNVP-polymers as a promising polyethyleneglycol (PEG) alternative onto anti-tumor lipoplexes surface [Paper presentation]. CIRM-Day, Liege, Belgium.

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (02 February 2022). Formulation and Quality Consideration of Cannabidiol Printlets Produced by Fused-Deposition Modeling [Paper presentation]. CIRM DAY 2022.

Koch, N., Jennotte, O., Lechanteur, A., & Evrard, B. (02 February 2022). Development of cannabidiol lipid-dispersion tablets: excipients selection and tabletability [Paper presentation]. CIRM Day 2022.

Nyamba, I., Sombié, C., Lechanteur, A., Semdé, R., & Evrard, B. (02 February 2022). Complexation with cyclodextrins and solid dispersions formation as physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid [Paper presentation]. CIRM Day 2022, Liège, Belgium.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (02 February 2022). Developement of stable amorphous solid dispersions by hot-melt extrusion coupled with 3D printing to enhance the dissolution rate of a BCSII active molecule: Impact of infill density and polymer composition [Paper presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Koch, N., Jennotte, O., Ziemons, E., Boussard, G., Lechanteur, A., & Evrard, B. (2022). Influence of API physico-chemical properties on amorphization capacity of several mesoporous silica loading methods. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.121372

Lechanteur, A., Plougonven, E., Orozco, L., Lumay, G., Vandewalle, N., Léonard, A., & Evrard, B. (2022). Engineered-inhaled particles: Influence of carbohydrates excipients nature on powder properties and behavior. International Journal of Pharmaceutics, 121319. doi:10.1016/j.ijpharm.2021.121319

Lechanteur, A. (December 2021). Mechanisms of drug delivery in the lung [Paper presentation]. Belgian Pneumology Days 2021.

Nyamba, I., Charle SOMBIE, Lechanteur, A., Rasmané Semdé, & Evrard, B. (03 November 2021). Augmentation de la solubilité et de la biodisponibilité de l’acide ellagique par complexation à l’aide de cyclodextrines en vue de son utilisation comme antipaludique: formulation et caractérisation par spectroscopie infrarouge à transformée de Fourier [Paper presentation]. Congrès, Ouagadougou, Burkina Faso.

Lechanteur, A. (November 2021). Mechanisms of drug delivery in the lung [Paper presentation]. CRS IC local chapter.

Parulski, C., Jennotte, O., Lechanteur, A., & Evrard, B. (August 2021). Challenges of fused deposition modeling 3D printing in pharmaceutical applications: Where are we now? Advanced Drug Delivery Reviews, 175. doi:10.1016/j.addr.2021.05.020

Ilangala Booka, A., Lechanteur, A., Fillet, M., & Piel, G. (2021). Therapeutic peptides for chemotherapy: trends and challenges for advanced delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2021.07.010

Berger, M., Lechanteur, A., Evrard, B., & Piel, G. (2021). Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now? International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120851

Toussaint, F., Berger, M., Sanaa, B. D., Lechanteur, A., Jérôme, C., Piel, G., Mottet, D., & Debuigne, A. (27 May 2021). Polyvinylpyrrolidone compounds as PEG alternatives for lipoplex modification [Poster presentation]. Belgian Polymer Group (BPG) Annual Meeting, remote, Belgium.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (26 May 2021). How do polymer composition and infill density of 3D printed tablets influence the dissolution rate of itraconazole ? [Paper presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Koch, N., Jennotte, O., Lechanteur, A., & Evrard, B. (14 May 2021). Improvement of fenofibrate aqueous solubility by using mesoporous silica impregnation under pressurized carbon dioxide [Poster presentation]. PBP 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

Berger, M., Toussaint, F., Ben Djemaa, S., Evrard, B., Jérôme, C., Debuigne, A., Mottet, D., Lechanteur, A., & Piel, G. (May 2021). Impact of amphiphilic N-vinyl pyrrolidone-based polymers used as PEG alternative on lipoplexes physico-chemical properties, cytotoxicity and gene delivery [Poster presentation]. Center for Interdisciplinary Research on Medicines (CIRM) Scientific Day, Liège, Belgium.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (06 April 2021). Amphiphilic N-vinyl pyrrolidone-based polymers as PEG alternatives to avoid blood proteins adsorption around liposomes [Paper presentation]. Early Career Scientist Meeting 2021.

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (06 April 2021). Amorphous solid dispersions of cannabidiol with an increase of the aqueous solubility: influence of the carrier, the hot melt extrusion parameters and the use of a crystallization inhibitor [Paper presentation]. The Controlled Release Society BeNeLux&France Early Career Scientists Meeting 2021.

Koch, N., Jennotte, O., Lechanteur, A., & Evrard, B. (06 April 2021). Influence of API physico-chemical properties on amorphization capacity of several mesoporous silica loading methods [Paper presentation]. CRS BNFL ECS Meeting 2021.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (06 April 2021). How do infill density and polymer composition of tablets produced by hotmelt extrusion coupled with Fused Deposition Modeling 3D printing influence the dissolution profile of a BCS II molecule ? [Paper presentation]. CRS Local Chapter Meeting.

Berger, M., Toussaint, F., Pairoux, C., Evrard, B., Jérôme, C., Lechanteur, A., Debuigne, A., & Piel, G. (04 March 2021). Impact of amphiphilic copolymer used as PEG alternative on the formation of a protein corona around coated-liposomes encapsulating siRNA [Paper presentation]. 2021 - Virtual Local Chapter Meeting Germany and BeNeLux & France, Aachen, Germany.

Parulski, C., Gresse, E., Jennotte, O., Lechanteur, A., & Evrard, B. (04 March 2021). Investigation of the impact of polymer composition and infill density of solid oral forms produced by hot-melt extrusion coupled with 3D printing on the dissolution rate of itraconazole [Paper presentation]. CRS Local Chapter Meeting, Aachen, Germany.

Bellefroid, C., Reusch, C., Lechanteur, A., Evrard, B., Debacq-Chainiaux, Mottet, D., & Piel, G. (2021). Systematic study of liposomes composition towards efficient delivery of plasmid DNA as potential application of dermal fibroblasts targeting. International Journal of Pharmaceutics, 592, 120122. doi:10.1016/j.ijpharm.2020.120122

Delma, K. L., Lechanteur, A., Semde, R., Evrard, B., & Piel, G. (2021). Sterilization methods of liposomes: drawbacks of conventional methods and perspectives. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2021.120271

Nyamba, I., Lechanteur, A., Semdé, R., & Evrard, B. (2020). Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: A review. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2020.11.004

Koch, N., Jennotte, O., Grignard, B., Lechanteur, A., & Evrard, B. (01 July 2020). Impregnation of mesoporous silica with poor aqueous soluble molecule using pressurized carbon dioxide: is the solubility in the supercritical and subcritical phase a critical parameter? European Journal of Pharmaceutical Sciences, 150, 105332. doi:10.1016/j.ejps.2020.105332

Lechanteur, A., & Evrard, B. (2020). Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review. Pharmaceutics. doi:10.3390/pharmaceutics12010055

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (2020). Three-dimensional printing technology as a promising tool in bioavailability enhancement of poorly water-soluble molecules: a review. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2020.119200

Koch, N., Jennotte, O., Gasparrini, Y., Vandenbroucke, F., Lechanteur, A., & Evrard, B. (2020). Cannabidiol aqueous solubility enhancement: comparison of three amorphous formulations strategies using different type of polymers. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2020.119812

Schmitt, C., Lechanteur, A., Cossais, F., Bellefroid, C., Arnold, P., Lucius, R., Held-Feindt, J., Piel, G., & Hattermann, K. (2020). Liposomal Encapsulated Curcumin Effectively Attenuates Neuroinflammatory and Reactive Astrogliosis Reactions in Glia Cells and Organotypic Brain Slices. International Journal of Nanomedicine, 15, 3649—3667. doi:10.2147/IJN.S245300

Bellefroid, C., Lechanteur, A., Evrard, B., Mottet, D., Debacq-Chainiaux, F., & Piel, G. (15 December 2019). In vitro skin penetration enchancement techniques: a combined approach of ethosomes and microneedles. International Journal of Pharmaceutics, 572. doi:10.1016/j.ijpharm.2019.118793

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (11 December 2019). Lipid-based nanovectors combined with microneedles to enhance skin penetration of genes: in vitro and in vivo studies [Paper presentation]. 2nd CIRM DAY, Liège, Belgium.

Ilangala Booka, A., COBRAIVILLE, G., EVRARD, A., Sonveaux, Lechanteur, A., Piel, G., & Fillet, M. (11 December 2019). LC-UV as tool for nanovectorized anticancer peptide quality control: evaluation of encapsulation efficiency [Poster presentation]. 2nd Edition of CIRM day, Liege, Belgium.

Jennotte, O., Koch, N., Lechanteur, A., & Evrard, B. (11 December 2019). Hot-melt extrusion as a solvent-free technique for the formation of a polymeric amorphous solid dispersion of atorvastatin [Paper presentation]. Second scientific CIRM day, Liège, Belgium.

Koch, N., Jennotte, O., Lechanteur, A., & Evrard, B. (11 December 2019). Improvement of fenofibrate aqueous solubility by using mesoporous silica impregnation under pressurized carbon dioxide [Paper presentation]. 2nd CIRM Day.

Lechanteur, A., Evrard, B., & Piel, G. (11 December 2019). Assessment of the feasibility to develop a fast and easy reproducible 3D bronchial model growing at the air-liquid interface: Which critical culture parameters must be controlled? [Poster presentation]. 2nd CIRM Day.

Nyamba, I., Lechanteur, A., Evrard, B., & SEMDE, R. (11 December 2019). Improvement water-solubility of ellagic acid for use as an antimalarial drug through oral administration [Poster presentation]. CIRM DAY, LIEGE, Belgium.

Sounouvou, A. G. H. T., Toukourou, H., Lechanteur, A., Piel, G., Quetin-Leclercq, J., Gbaguidi, F., & Evrard, B. (11 December 2019). Development of dermatological dosage forms based on essential oils for the treatment of common skin infections [Paper presentation]. 2nd CIRM day, Liege, Belgium.

Sounouvou, A. G. H. T., Lechanteur, A., Quetin-Leclercq, J., Piel, G., Donneau, A.-F., Gbaguidi, F., & Evrard, B. (2019). Chromametric assessment of drug skin tolerance: A comparative study between Africans and Caucasians skins. Skin Research and Technology. doi:10.1111/srt.12804

Nyamba, I., Charles Sombié, Lechanteur, A., Rasmané Semdé, & Evrard, B. (27 October 2019). Amélioration de la solubilité et de la biodisponibilité de l’acide ellagique en vue de son utilisation comme antipaludique [Paper presentation]. Congrès, Abidjan, Côte d’Ivoire.

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (24 September 2019). Nucleic acids skin penetration enhancement: a combined approach of deformable liposomes and microneedles [Paper presentation]. Skin & Formulation 5th Symposium & 17th Skin Forum, Reims, France.

Lechanteur, A., Evrard, B., & Piel, G. (2019). Assessment of the feasibility to develop a fast and easy reproducible 3D bronchial model growing at the air-liquid interface: Which critical culture parameters must be controlled? European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2019.09.001

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (20 May 2019). Improvement of skin penetration of lipid-based nanocarriers according to their composition [Paper presentation]. 20th Forum of Pharmaceutical Sciences, Bruxelles, Belgium.

Jennotte, O., Koch, N., Rocks, N., Lechanteur, A., & Evrard, B. (20 May 2019). Development of new manufacturing processes for amorphous solid dispersions [Paper presentation]. 20th forum of pharmaceutical sciences, Bruxelles, Belgium.

Koch, N., Jennotte, O., Rocks, N., Lechanteur, A., & Evrard, B. (20 May 2019). Mesoporous silica impregnation using supercritical carbon dioxide: is the solubility in the supercritical fluid a critical parameter? [Paper presentation]. 20th Forum of Pharmaceutical Sciences, Bruxelles, Belgium.

Jennotte, O., Koch, N. (Other coll.), Collard, L. (Other coll.), Lechanteur, A. (Other coll.), & Evrard, B. (Other coll.). (26 March 2019). Hot melt extrusion as a solvent-free technique for the formation of a polymeric amorphous solid dispersion of atorvastatin [Poster presentation]. 3rd European Conference on Pharmaceutics, Bologne, Italy.

Koch, N., Jennotte, O., Rocks, N., Lechanteur, A., & Evrard, B. (26 March 2019). Impregnation of mesoporous silica using supercritical-CO2: is the solubility in the supercritical fluid a critical paramter? [Poster presentation]. 3rd European Conference on Pharmaceutics, Bologne, Italy.

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (25 March 2019). Enhancement of skin penetration of lipid-based nanocarriers [Paper presentation]. 3th European Conference on Pharmaceutics, Bologne, Italy.

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (2019). Lipid gene nanocarriers for the treatment of skin diseases: current state-of-the-art. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2019.02.012

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (19 December 2018). Enhancement of skin penetration of lipid-based nanocarriers [Paper presentation]. 1st CIRM Scientific Day, Liège, Belgium.

Jennotte, O., Koch, N., Collard, L., Lechanteur, A., & Evrard, B. (19 December 2018). Hot melt extrusion as a solvent-free technique for the formation of a polymeric amorphous solid dispersion of atorvastatin [Paper presentation]. CIRM Day, Liège, Belgium.

Koch, N., Jennotte, O., Rocks, N., Lechanteur, A., & Evrard, B. (December 2018). Impregnation of mesoporous silica with fenofibrate using supercritical-CO2: is the solubility a critical parameter? [Paper presentation]. 1st CIRM scientific Day, Liège, Belgium.

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (August 2018). Assessment of skin penetration of classical and deformable liposomes [Poster presentation]. 12th International Conference and Workshop on Biological Barriers, Saarbrücken, Germany.

Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., & Piel, G. (August 2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape [Paper presentation]. 12th International Conference and Workshop on Biological barriers, Saarbruck, Germany.

Bellefroid, C., Lechanteur, A., Evrard, B., & Piel, G. (12 July 2018). Assessment of skin penetration of classical and deformable liposomes [Paper presentation]. First NANOMED EMJMD's Workshop, Paris, France.

Angeli de Lima, I., Maissar Khalil, N., Toyomi Tominaga, T., Lechanteur, A., Sarmento, B., & Mara Mainardes, R. (2018). Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid. Artificial Cells, Nanomedicine and Biotechnology. doi:10.1080/21691401.2018.1477788

Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., & Piel, G. (2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape. In Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape.

Piel, G., Lechanteur, A., & Cao, M. (17 January 2018). Update on the progresses and development prospects of the unifying theme "nanomedicine" within CIRM [Paper presentation]. CIRM seminar, Liege, Belgium.

Boni, F. I., Almeida, A., Lechanteur, A., Sarmento, B., Stringhetti Ferreira Cury, B., & Palmira Daflon Gremião, M. (01 January 2018). Mucoadhesive nanostructured polyelectrolytes complexes modulate the intestinal permeability of methotrexate. European Journal of Pharmaceutical Sciences, 111. doi:10.1016/j.ejps.2017.09.042

Lechanteur, A., Sanna, V., Duchemin, A., Evrard, B., Mottet, D., & Piel, G. (2018). Cationic Liposomes Carrying siRNA: Impact of Lipid Composition on Physicochemical Properties, Cytotoxicity and Endosomal Escape. Nanomaterials, 8 (5). doi:10.3390/nano8050270

Pereira, I., Lechanteur, A., & Sarmento, B. (2018). 3D Model Replicating the Intestinal Function to Evaluate Drug Permeability. In Epithelial Cell Culture: Methods and Protocols. Springer Nature. doi:10.1007/978-1-4939-8600-2_11

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (07 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. SF Nano Annual Meeting 2017, Bordeaux, France.

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (05 December 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 4th SF Nano Annual Meeting, Bordeaux, France.

Sgorla, D., Lechanteur, A., Almeida, A., Sousa, F., Melo, E., Bunhak, É., Mainardes, R., Khalil, N., Cavalcanti, O., & Sarmento, B. (2017). Development and characterization of lipid-polymeric nanoparticles for oral insulin delivery. Expert Opinion on Drug Delivery. doi:10.1080/17425247.2018.1420050

Lechanteur, A., das Neves, J., & Sarmento, B. (2017). The role of mucus in cell-based models used to screen mucosal drug delivery. Advanced Drug Delivery Reviews. doi:10.1016/j.addr.2017.07.019

Lechanteur, A., Almeida, A., & Sarmento, B. (2017). Elucidation of the impact of cell culture conditions of Caco-2 cell monolayer on barrier integrity and intestinal permeability. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2017.06.013

Lechanteur, A., Furst Tania, Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (25 April 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 1st SPLC-Controlled Release Society, Santiago de Compostela, Spain.

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (04 April 2017). Promoting vaginal distribution of two active siRNA-complexed in liposomes for cervical cancer treatment [Paper presentation]. 2nd European Conference on Pharmaceutics: Drug Delivery, Krakow, Poland.

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Piel, G., & Hubert, P. (2017). Promoting vaginal distribution of E7 and MCL-1 siRNA-silencing nanoparticles for cervical cancer treatment. Molecular Pharmaceutics. doi:10.1021/acs.molpharmaceut.6b01154

Lechanteur, A., Furst, T., Evrard, B., DELVENNE, P., Hubert, P., & Piel, G. (27 September 2016). FINDING THE RIGHT BALANCE BETWEEN EFFECTIVENESS, TOXICITY AND VAGINAL DIFFUSION OF siRNA LIPOPLEXES FOR CERVICAL CANCER TREATMENT [Poster presentation]. 4th Conference on Innovation in Drug Delivery: Site specific drug delivery, Antibes, France.

Furst, T., Dakwar, G., zagato, E., Lechanteur, A., Remaut, K., Evrard, B., De Smedt, S., & Piel, G. (26 September 2016). MUCOADHESIVE SPONGES WITH PEGYLATED LIPOPLEXES: TOWARDS A SUSTAINED VAGINAL DELIVERY OF siRNA [Poster presentation]. 4th Conference on Innovation in Drug Delivery: Site specific drug delivery, Antibes, France.

Lechanteur, A. (2016). Développement et optimisation de nanovecteurs de type lipoplexes pour une application vaginale en vue de traiter des lésions induites par HPV [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/215358

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (August 2016). PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness. European Journal of Pharmaceutical Sciences, 93, 493-593. doi:10.1016/j.ejps.2016.08.058

Furst, T., Bettonville, V., Farcas, E., Frère, A., Lechanteur, A., Evrard, B., Fillet, M., Piel, G., & Servais, A.-C. (2016). Capillary electrophoresis method to determine siRNA complexation with cationic liposomes. Electrophoresis. doi:10.1002/elps.201600249

Furst, T., Dakwar, G. R., Zagato, E., Lechanteur, A., Remaut, K., Evrard, B., Braeckmans, K., & Piel, G. (2016). Freeze-dried mucoadhesive polymeric system containing pegylated lipoplexes: Towards a vaginal sustained released system for siRNA. Journal of Controlled Release. doi:10.1016/j.jconrel.2016.06.028

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (28 May 2015). DEVELOPMENT OF LIPOPLEXES FOR A TOPICAL TREATMENT OF HPV16 INDUCED LESIONS: In vitro and ex vivo studies [Paper presentation]. 18th Forum of Pharmaceutical Sciences, Blankenberg, Belgium.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (13 May 2015). Anti-E6/E7/MCL1 pegylated lipoplexes for a topical treatment of HPV16 induced lesions [Paper presentation]. GIGA-Cancer Day 2015, Liege, Belgium.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (14 April 2015). Anti-E6/E7/MCL1 pegylated lipoplexes for a vaginal treatment of cervical cancer [Paper presentation]. 1st European Conference on Pharmaceutics Drug Delivery, Reims, France.

Furst, T., Lechanteur, A., Evrard, B., & Piel, G. (13 April 2015). Mucoadhesive hydroxyethyl-cellulose sponges as lipoplexes delivery system for vaginal application [Poster presentation]. 1st European Conference on Pharmaceutics: Drug Delivery, Reims, France.

Lechanteur, A.* , Furst, T.* , Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (16 February 2015). Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. International Journal of Pharmaceutics, 483, 268-277. doi:10.1016/j.ijpharm.2015.02.041
* These authors have contributed equally to this work.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (11 February 2015). Anti-E6/E7/MCL1 pegylated lipoplexes for a topical treatment of cervical (pre)neoplastic lesions [Poster presentation]. Séminaire des chercheurs Télévie 2015, Bruxelles, Belgium.

Furst, T., Piette, M., Lechanteur, A., Evrard, B., & Piel, G. (2015). Mucoadhesive cellulosic derivative sponges as drug delivery system for vaginal application. European Journal of Pharmaceutics and Biopharmaceutics. doi:10.1016/j.ejpb.2015.01.019

Lechanteur, A., Furst, T., Delvenne, P., Evrard, B., Hubert, P., & Piel, G. (2015). Anti-E6/E7/MCL-1 pegylated lipoplexes for a vaginal treatment of cervical cancer [Paper presentation]. 1st European Conference on Pharmaceutics: Drug Delivery, Reims, France.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 November 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 2014 AAPS Annual Meeting and Exposition, San Diego, United States.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (20 October 2014). DEVELOPMENT AND CHARACTERIZATION OF PEGYLATED LIPOPLEXES TO BE ENTRAPPED IN HEC SPONGES FOR VAGINAL DELIVERY [Poster presentation]. 3rd NanoFar Autumn School, Louvain, Belgium.

Lechanteur, A., Furst, T., Kanber, E., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (04 October 2014). Development and optimization of pegylated lipoplexes for vaginal application [Paper presentation]. SFNano Workshop 2014, Porto, Portugal.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (27 August 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES TO BE INCORPORATED INTO MUCOADHESIVE HEC-SPONGES [Poster presentation]. Translational Nanomedicine, International Meeting, Angers, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (19 May 2014). ASSOCIATION OF LIPOSOMES AND siRNA FOR A LOCAL TREATMENT OF CERVICAL CANCER [Poster presentation]. GIGA-Cancer Day 2014.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (03 April 2014). DEVELOPMENT OF PEG-COATED LIPOPLEXES WITH siRNA ANTI E6/E7 ONCOPROTEINS FOR THE TREATMENT OF HPV CANCERS [Poster presentation]. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbonne, Portugal.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (16 February 2014). Development of PEG-coated lipoplexes with siRNA anti-E6/E7 oncoproteins to be incorporated into mucoadhesive HEC-sponges for the treatment of HPV cancers [Poster presentation]. 10th International Conference and Workshop on Biological Barriers, Saarbrucken, Germany.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (16 February 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. 10th International conference and workshop on Biological Barriers.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (27 January 2014). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. GIGA-Day 2014.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (05 December 2013). Development of anti-HPV lipoplexes formulations for the treatment of cervical cancer [Poster presentation]. Séminaire des chercheurs du Télévie 2014.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (03 December 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. 28ième Journées Scientifiques du GTRV, Angers, France.

Furst, T., Lechanteur, A., Hubert, P., Evrard, B., & Piel, G. (02 December 2013). Development of peggylated lipoplexes with siRNA anti-E6/E7 oncoproteins for the treatment og cancers induced by HPV [Poster presentation]. GTRV, Orléans, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (17 October 2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Paper presentation]. Dix-septième forum des sciences pharmaceutiques.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Piel, G., & Hubert, P. (17 June 2013). Développement et optimisation de vecteur de type lipoplexe pour une approche thérapeutique antisens dans le cadre de lésions induites par HPV [Paper presentation]. Séminaire C.I.R.M.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., RONCARATI, P., Piel, G., & Hubert, P. (2013). Development of anti-HPV lipoplexes for the treatment of cervical cancer [Poster presentation]. Cancer GIGA-Day 2013, liège, Belgium.

Lechanteur, A., Evrard, B., Delvenne, P., RONCARATI, P., Hubert, P., & Piel, G. (November 2012). Development and optimization of lipoplex vectors for an antisens therapeutic approach in the context of HPV induced lesions [Poster presentation]. Ecole doctorale en cancérologie expérimentale, liège, Belgium.

Furst, T., Lechanteur, A., Evrard, B., Delvenne, P., Hubert, P., Piette, M., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar 1st Autumn School, Angers, France.

Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., & Piel, G. (22 October 2012). Development of a topical formulation containing lipoplexes able to inhibit E6 and E7 genes for the treatment of cervix cancer caused by HPV16 and HPV18 [Poster presentation]. NanoFar Automn School, Angers, France.